Arterolane/piperaquine

Drug Profile

Arterolane/piperaquine

Alternative Names: Arterolane maleate/piperaquine phosphate; Synriam

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Medicines for Malaria Venture; Ranbaxy Laboratories
  • Developer Sun Pharmaceutical Industries
  • Class 1 ring heterocyclic compounds; Antimalarials; Peroxides; Piperazines; Quinolines; Small molecules; Spiro compounds
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria; Vivax malaria

Most Recent Events

  • 06 Aug 2015 Launched for Falciparum malaria in Nigeria (PO) before August 2015
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 15 Dec 2014 Launched for Falciparum malaria in Uganda (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top